Price T Rowe Associates Inc Denali Therapeutics Inc. Transaction History

Price T Rowe Associates Inc

$816 Billion
Q1 2024

A detailed history of Price T Rowe Associates Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,594,333 shares of DNLI stock, worth $37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,594,333

Previous 2,574,321 38.07%

Holding current value

$37 Million

Previous $55.2 Million 40.78%

% of portfolio

0.0%

Previous 0.01%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$15.83 - $23.35 $15.5 Million - $22.9 Million	-979,988 Reduced 38.07%	1,594,333 $32.7 Million
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $5.15 Million - $7.36 Million	-317,629 Reduced 10.98%	2,574,321 $55.2 Million
Q3 2023 Nov 14, 2023	SELL	$20.63 - $30.17 $11.4 Million - $16.7 Million	-553,362 Reduced 16.06%	2,891,950 $59.7 Million
Q2 2023 Aug 14, 2023	SELL	$23.37 - $32.96 $2.16 Million - $3.05 Million	-92,466 Reduced 2.61%	3,445,312 $102 Million
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $2.43 Million - $3.63 Million	-111,110 Reduced 3.05%	3,537,778 $81.5 Million

Q4 2022 Feb 14, 2023	BUY	$26.28 - $33.92 $4.48 Million - $5.78 Million	170,520 Added 4.9%	3,648,888 $101 Million
Q3 2022 Nov 14, 2022	SELL	$25.97 - $38.53 $29.4 Million - $43.6 Million	-1,131,809 Reduced 24.55%	3,478,368 $107 Million
Q2 2022 Aug 15, 2022	SELL	$20.88 - $35.19 $6.54 Million - $11 Million	-313,248 Reduced 6.36%	4,610,177 $136 Million
Q1 2022 May 16, 2022	BUY	$29.0 - $47.27 $8.35 Million - $13.6 Million	287,992 Added 6.21%	4,923,425 $158 Million
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $5.22 Million - $6.74 Million	-122,532 Reduced 2.58%	4,635,433 $207 Million
Q3 2021 Nov 15, 2021	SELL	$48.48 - $78.23 $7.05 Million - $11.4 Million	-145,487 Reduced 2.97%	4,757,965 $240 Million
Q2 2021 Aug 16, 2021	SELL	$50.3 - $78.44 $58.1 Million - $90.6 Million	-1,154,827 Reduced 19.06%	4,903,452 $385 Million
Q1 2021 May 17, 2021	SELL	$53.8 - $81.53 $21.9 Million - $33.1 Million	-406,547 Reduced 6.29%	6,058,279 $346 Million
Q4 2020 Feb 16, 2021	BUY	$36.89 - $93.56 $238 Million - $605 Million	6,464,826 New	6,464,826 $541 Million

Others Institutions Holding DNLI

# of Institutions

217

Shares Held

115M

Call Options Held

142K

Put Options Held

90.3K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.12B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Denali Therapeutics Inc. Transaction History